Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jiangsu Hengrui Pharmaceuticals CoFRA:0BO +1.98%90 Equity-to-Asset is 0.91 as of Jun. 2026, which is 2% above its 10-year median of 0.89. GuruFocus rates FRA:0BO with a GF Score™ of 90/100 and a GF Value™ of €6.56 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Jiangsu Hengrui Pharmaceuticals Co ranks better than 94.84% on this metric.
The historical rank and industry rank for Jiangsu Hengrui Pharmaceuticals Co's Equity-to-Asset or its related term are showing as below:
FRA:0BO'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.85 Med: 0.89 Max: 0.93
Current: 0.91
During the past 13 years, the highest Equity to Asset Ratio of Jiangsu Hengrui Pharmaceuticals Co was 0.93. The lowest was 0.85. And the median was 0.89.
FRA:0BO's Equity-to-Asset is ranked better than 94.84% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs FRA:0BO: 0.91
Jiangsu Hengrui Pharmaceuticals Co (FRA:0BO) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Jiangsu Hengrui Pharmaceuticals Co Equity-to-Asset Related Terms
Jiangsu Hengrui Pharmaceuticals Co Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Hengrui Pharmaceuticals Co Equity-to-Asset Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Hengrui Pharmaceuticals Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Hengrui Pharmaceuticals Co Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Hengrui Pharmaceuticals Co's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Jiangsu Hengrui Pharmaceuticals Co's Equity-to-Asset falls into.
Jiangsu Hengrui Pharmaceuticals Co Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Hengrui Pharmaceuticals Co (FRA:0BO) has a Equity-to-Asset of 0.91 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. This is near median its historical median of 0.89. Over the past decade, Jiangsu Hengrui Pharmaceuticals Co's Equity-to-Asset has ranged from 0.85 to 0.93. According to the industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #52 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 5.2%.
Is Jiangsu Hengrui Pharmaceuticals Co's Equity-to-Asset too high?
Jiangsu Hengrui Pharmaceuticals Co's current Equity-to-Asset of 0.91 is near median its 10-year median of 0.89. Over the past 10 years, this metric has ranged from a low of 0.85 to a high of 0.93. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Jiangsu Hengrui Pharmaceuticals Co's value of 0.91 is 51.7% above this industry median. Based on the distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #52 out of 1008 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jiangsu Hengrui Pharmaceuticals Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Hengrui Pharmaceuticals Co's Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #52 out of 1008 companies for Equity-to-Asset. This places Jiangsu Hengrui Pharmaceuticals Co in the top 5% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.60. Jiangsu Hengrui Pharmaceuticals Co's value of 0.91 is 51.7% above this benchmark. Historically, Jiangsu Hengrui Pharmaceuticals Co's own Equity-to-Asset has ranged from 0.85 to 0.93 over the past decade. While the company's 10-year median is 0.89 vs. the industry median of 0.60, Jiangsu Hengrui Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Hengrui Pharmaceuticals Co's current Equity-to-Asset of 0.91 is 51.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Hengrui Pharmaceuticals Co's current Equity-to-Asset is 0.91, which is near median its own 10-year median of 0.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Hengrui Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co (FRA:0BO) is currently considered Modestly Undervalued. The stock's GF Value™ is €6.56, compared to a current price of €5.15 — trading 21.5% below its estimated fair value. The current Equity-to-Asset is 0.91, which is near median its 10-year median of 0.89 and 51.7% above the Drug Manufacturers industry median of 0.60. Jiangsu Hengrui Pharmaceuticals Co's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Jiangsu Hengrui Pharmaceuticals Co (FRA:0BO), the current Equity-to-Asset is 0.91 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Hengrui Pharmaceuticals Co (FRA:0BO) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co stock appears to be undervalued.
The current stock price of €5.15 is trading 21.5% below its estimated GF Value™ of €6.56.
GuruFocus considers Jiangsu Hengrui Pharmaceuticals Co to be Modestly Undervalued.
Key valuation signals for FRA:0BO:
Equity-to-Asset: 0.91 (near median its 10-year median of 0.89)
GF Value™: €6.56 vs. price of €5.15 (21.5% below fair value)
Industry Position: 51.7% above the Drug Manufacturers median (#52 of 1008)
No single metric tells the full story. See the FRA:0BO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
90GF Score
Get the complete analysis for FRA:0BO
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0BO has been successfully added to your 
